The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
High DNA input and next-generation sequencing peripheral blood MRD detection in patients with BCP-ALL
|
A retrospective analysis selected paired BM-PB samples from 69 patients with BCP-ALL where MRD was detected in the BM by conventional RT-qPCR but not in the PB.1 Samples were reanalyzed with heightened sensitivity using increased DNA input and amplicon-based NGS. Results from this analysis were published in the British Journal of Haematology by Bendig et al.1
|
| Key learnings |
| In PB samples using high DNA input RT-qPCR, standard DNA input NGS, and high DNA input NGS, MRD was detected in 32%, 23%, and 48% of samples, respectively. |
| Considering all possible IGH markers improved NGS MRD detection in 52% of PB samples. |
| Despite improved detection in PB, MRD levels remained consistently low in PB compared with BM, indicating that PB monitoring alone may not fully replace BM analysis and relying on PB alone could delay early relapse detection. |
| Results from this analysis suggest that analysis of PB samples with high DNA input and NGS could be considered when BM samples are unavailable in patients with BCP-ALL. |
Abbreviations: BCP-ALL, B-cell precursor acute lymphoblastic leukemia; BM, bone marrow; IGH, immunoglobulin heavy chain; MRD, measurable residual disease; NGS, next-generation sequencing; PB, peripheral blood; RT-qPCR, real-time quantitative polymerase chain reaction.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
